β-blocking agents

Drugs for the Heart: Expert Consult - Online and Print

Volumn , Issue , 2013, Pages 1-37

  Opie, Lionel H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85131478168     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-3322-4.00010-7     Document Type: Chapter

References (119)

1. Brodde OE Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure Naunyn Schmiedebergs Arch Pharmacol 374 2007 361-372.
2. Opie LH., et al.Cardiac survival strategies an evolutionary hypothesis with rationale for metabolic therapy of acute heart failure Transact Royal Soc South Africa 65 2010 185-189.
3. DiPilato LM., et al. FRETting mice shed light on cardiac adrenergic signaling Circ Res 99 2006 1021-1023.
4. Lefkowitz RJ., et al. Transduction of receptor signals by beta-arrestins Science 308 2005 512-517.
5. Dessy C., et al. Endothelial beta-3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol Circulation 112 2005 1198-1205.
6. Heusch G Beta(3)-adrenoceptor activation just says NO to myocardial reperfusion injury J Am Coll Cardiol 58 2011 2692-2694.
7. Wallhaus TR., et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure Circulation 103 2001 2441-2446.
8. Brodde OE., et al.Cardiac adrenoceptors physiological and pathophysiological relevance J Pharmacol Sci 100 2006 323-337.
9. Heilbrunn SM., et al. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy Circulation 79 1989 483-490.
10. Boden WE., et al. Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503-1516.
11. Poole-Wilson PA., et al.Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial) randomised controlled trial Lancet 364 2004 849-857.
12. Kugiyama K., et al.Effects of propranolol and nifedipine on exercise-induced attack in patients with variant angina assessment by exercise thallium-201 myocardial scintigraphy with quantitative rotational tomography Circulation 74 1986 374-380.
13. Peart I., et al.Cold intolerance in patients with angina pectoris effect of nifedipine and propranolol Br Heart J 61 1989 521-528.
14. Kern MJ., et al. Potentiation of coronary vasoconstriction by beta-adrenergic blockade in patients with coronary artery disease Circulation 67 1983 1178-1185.
15. ASIST study Pepine C., et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST Circulation 90 1994 762-768.
16. Mukherjee D., et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes Circulation 109 2004 745-749.
17. Yusuf S., et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction Circulation 67 Suppl I 1983 I32-I41.
18. HINT Study. Early treatment of unstable angina in the coronary care unit, a randomised, double-blind placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Holland Inter-university Nifedipine Trial Br Heart J 56 1986 400-413.
19. Miller CD., et al. Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction Am J Med 120 2007 685-692.
20. Ryden L., et al. A double-blind trial of metoprolol in acute myocardial infarction N Engl J Med 308 1983 614-618.
21. Norris RM., et al. Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol 1984 Lancet 883-886.
22. Chen ZM., et al.Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction randomised placebo-controlled trial Lancet 366 2005 1622-1632.
23. Bates ERRole of intravenous beta-blockers in the treatment of ST-elevation myocardial infarction of mice (dogs, pigs) and men Circulation 115 2007 2904-2906.
24. Antman EM., et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction Circulation 117 2008 296-329.
25. Smith SC JrSecondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease 2011 updatea guideline from the AHA and ACC Foundation Circulation 124 2011 2458-2473.
26. Freemantle N., et al.β-blockade after myocardial infarction systemic review and meta regression analysis Br Med J 318 1999 1730-1737.
27. Gottlieb SS., et al. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction N Engl J Med 339 1998 489-497.
28. Olsson G., et al.Long-term treatment with metoprolol after myocardial infarction effect on 3-year mortality and morbidity J Am Coll Cardiol 5 1985 1428-1437.
29. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction the CAPRICORN randomised trial Lancet 357 2001 1385-1390.
30. Teo KK., et al.Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction an overview of results from randomized controlled trials JAMA 270 1993 1589-1595.
31. SAVE Study Pfeffer MA., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial N Eng J Med 327 1992 669-677.
32. Heidenreich PA., et al. Meta-analysis of trials comparing b-blockers, calcium antagonists, and nitrates for stable angina JAMA 281 1999 1927-1936.
33. Krause T., for the Guideline Development Group., et al.Management of hypertension summary of NICE guidance Br Med J 343 2011 Aug 25 d4891.
34. Dahlöf B., et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial Lancet 366 2005 895-906.
35. Lam SK., et al. Incident diabetes in clinical trials of antihypertensive drugs Lancet 369 2007 1514-1515.
36. Williams B Beta-blockers and the treatment of hypertension J Hypertens 25 2007 1351-1353.
37. Williams B., et al.Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 113 2006 1213-1225.
38. Chobanian AV., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure JAMA 289 2003 2560-2572.
39. Psaty BM., et al.Health outcomes associated with antihypertensive therapies used as first-line agents a systemic review and meta-analysis JAMA 277 1997 739-745.
40. Rosendorff C., et al.Treatment of hypertension in the prevention and management of ischemic heart disease a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation 115 2007 2761-2788.
41. Pepine CJ., et al.A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2003 2805-2816.
42. Ried LD., et al. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension treatment strategy in the International Verapamil SR-Trandolapril Study (INVEST) Psychosom Med 67 2005 398-406.
43. Messerli FH., et al. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review JAMA 279 1998 1903-1907.
44. Kjeldsen SE., et al. For the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy JAMA 288 2002 1491-1498.
45. Morgan T., et al. Effect of different antihypertensive drug classes on central aortic pressure Am J Hypertens 17 2004 118-123.
46. Materson BJ., et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents N Engl J Med 328 1993 914-921.
47. UKPDS 39 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 Br Med J 317 1998 713-720.
48. Dunder K., et al.Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction population based cohort study Br Med J 326 2003 681-685.
49. Lithell H., et al. Metabolic effects of carvedilol in hypertensive patients Eur J Clin Pharmacol 52 1997 13-17.
50. Gress TW., et al. For the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensives therapy as risk factors for type 2 diabetes mellitus N Engl J Med 342 2000 905-912.
51. Lubbe WH., et al.Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors J Am Coll Cardiol 19 1992 1622-1633.
52. Pogwizd SM., et al. Arrhythmogenesis and contractile dysfunction in heart failure Circ Res 88 2001 1159-1167.
53. Steinbeck G., et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias N Engl J Med 327 1992 987-992.
54. ESVEM Study Mason JWA comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias Electrophysiologic Study versus Electrocardiographic Monitoring Investigators N Engl J Med 329 1993 452-458.
55. Boutitie F., et al. Amiodarone interactions with beta-blockers. Analysis of the merged EMIAT (European Myocardial Infarct Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarct Trial) databases Circulation 99 1999 2268-2275.
56. Kennedy HL., et al. β-blocker therapy in the cardiac arrhythmia suppression trial Am J Cardiol 74 1994 674-680.
57. Ellison KE., et al. Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT) Circulation 106 2002 2694-2699.
58. Bardy GH., et al. Sudden cardiac death in heart failure trial (SCD-HeFT) investigators N Engl J Med 352 2005 225-237 Erratum in N Engl J Med 2005;352:2146.
59. Bradley D., et al.Pharmacologic prophylaxis American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery Chest 128 2005 39S-47S.
60. Lowes BD., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents N Engl J Med 346 2002 1357-1365.
61. Poole-Wilson PA., et al.Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET) randomised controlled trial Lancet 362 2003 7-13.
62. RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study Circulation 101 2000 378-384.
63. Opie LH., et al. Mechanisms of cardiac contraction and relaxation In: Bonow RO., et al.Braunwald’s heart disease a textbook of cardiovascular medicine9th edition 2011 Elsevier Saunders Philadelphia 459-486.
64. Baillie GS., et al. Beta-arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi Proc Natl Acad Sci U S A 100 2003 940-945.
65. Engelhardt SAlternative signaling cardiomyocyte beta1-adrenergic receptors signal through EGFRs J Clin Invest 117 2007 2396-2398.
66. Tzingounis AV., et al. Beta-blocker drugs mediate calcium signaling in native central nervous system neurons by beta-arrestin-biased agonism Proc Natl Acad Sci U S A 107 2010 21028-21033.
67. Penela P., et al. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease Cardiovasc Res 69 2006 46-56.
68. Chakir K., et al. Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy Circulation 119 2009 1231-1240.
69. Doi M., et al. Propranolol prevents the development of heart failure by restoring FKBP 12.6-mediated stabilization of ryanodine receptor Circulation 105 2002 1374-1379.
70. Kubo H., et al. Patients with end-stage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance Circulation 104 2001 1012-1018.
71. Reiken S., et al. β-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure Circulation 107 2003 2459-2466.
72. Cook S., et al.High heart rate a cardiovascular risk factor Eur Heart J 27 2006 2387-2393.
73. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure; 109 1674.
74. Engelhardt S., et al. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation Circulation 109 2004 1154-1160.
75. Communal C., et al.Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis role of a pertussis toxin-sensitive G protein Circulation 100 1999 2210-2212.
76. Packer M., et al. Consensus recommendations for the management of chronic heart failure Am J Cardiol 83 2A 1999 1A-38A.
77. Shekelle PG., et al.Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status a meta-analysis of major clinical trials J Am Coll Cardiol 41 2003 1529-1538.
78. Ghio S., et al.Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction results of the SENIORS echocardiographic substudy Eur Heart J 27 2006 562-568.
79. Sliwa K., et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure J Am Coll Cardiol 44 2004 1825-1830.
80. Willenheimer R., et al.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III Circulation 112 2005 2426-2435.
81. McAlister FA., et al.Meta-analysis beta-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784-794.
82. Rosso R., et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia Heart Rhythm 4 2007 1149-1154.
83. Sheldon R., et al.Prevention of Syncope Trial (POST) a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope Circulation 113 2006 1164-1170.
84. Sauer AJ., et al. Long QT syndrome in adults J Am Coll Cardiol 49 2007 329-337.
85. Liu N., et al. Catecholaminergic polymorphic ventricular tachycardia Herz 32 2007 212-217.
86. Raj SR., et al.Propranolol decreases tachycardia and improves symptoms in the Postural Tachycardia Syndrome (POTS) less is more Circulation 120 2009 725-734.
87. Fu Q., et al. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome Hypertension 58 2011 167-175.
88. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults principal resultsBr Med J 304 1992 405-412.
89. Webb AJ., et al.Effects of b-blocker selectivity on blood pressure variability and stroke a systematic review Neurology 77 2011 731-737.
90. Poldermans D., et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery N Engl J Med 341 1999 1789-1794.
91. Lindenauer PK., et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery N Engl J Med 353 2005 349-361.
92. Yang H., et al.The effects of perioperative beta-blockade results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial Am Heart J 152 2006 983-990.
93. Ismail R., et al. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients J Clin Pharm Ther 31 2006 99-109.
94. Fleischmann KE., et al.2009 ACCF/AHA focused update on perioperative beta blockade a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines Circulation 120 2009 2123-2151.
95. Groszmann RJ., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis N Engl J Med 353 2005 2254-2261.
96. TOMH Study Neaton JD., et al. Treatment of Mild Hypertension study (TOMH). Final results JAMA 270 1993 713-724.
97. Metra M., et al.Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure results from the COMET trial Eur Heart J 26 2005 2259-2268.
98. Kampus P., et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness Hypertension 57 2011 1122-1128.
99. Ito H., et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure Circ J 74 2010 1578-1583.
100. Bakris GL., et al.Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension a randomized controlled trial JAMA 292 2004 2227-2236.
101. Simpson WT Nature and incidence of unwanted effects with atenolol Postrgrad Med J 53 1977 162-167.
102. Conant J., et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility J Cardiovasc Pharmacol 13 1989 656-661.
103. Streufert S., et al. Impact of b-adrenergic blockers on complex cognitive functioning Am Heart J 116 1988 311-315.
104. Croog S., et al. The effects of antihypertensive therapy on the quality of life N Eng J Med 314 1986 1657-1664.
105. TAIM Study Wassertheil-Smoller S., et al. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk and quality of life Am J Hypertens 5 1992 37-44.
106. Fogari R., et al.Sexual activity in hypertensive men treated with valsartan or carvedilol a crossover study Am J Hypertens 14 2001 27-31.
107. Brixius K., et al.Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study) benefit of nebivolol versus metoprolol in hypertensive men Clin Exp Pharmacol Physiol 34 2007 327-331.
108. Boyd R., et al.Towards evidence based emergency medicine best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose Emerg Med J 20 2003 266-267.
109. Grimm RH., et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) Hypertension 29 1997 8-14.
110. Bangalore S., et al. Cardiovascular protection using beta blockers JACC 50 2007.
111. Jandeleit-Dahm KA., et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes J Hypertens 23 2005 463-473.
112. Dahlöf B., et al. For the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995-1003.
113. Lechat P., et al. Heart rate asnd cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial Circulation 103 2001 1428-1433.
114. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomized Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001-2007.
115. Broeders MA., et al.Nebivolol a third-generation beta-blocker that augments vascular nitric oxide releaseendothelial beta(2)-adrenergic receptor-mediated nitric oxide production Circulation 102 2000 677-684.
116. Van de Water A., et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist J Cardiovasc Pharmacol 11 1988 552-563.
117. Celik T., et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients J Hypertens 24 2006 591-596.
118. Hohnloser SH., et al. For the European Esmolol Study Group. Usefulness of esmolol in unstable angina pectoris Am J Cardiol 67 1991 1319-1323.
119. Koutouzis M., et al. Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction Drugs Aging 23 2006 673-680.